VANCOUVER, BC / ACCESS Newswire / March 30, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to provide an update on its semaglutide oral thin-film (ODF) program and its broader strategy to develop a scalable platform for GLP-1 receptor agonists and peptide-based therapeutics. Semaglutide as Lead Candidate for GLP-1 Platform Validation BioNxt is currently in early-stage development of its semaglutide ODF program, with initial formulation work underway, including preliminary feasibility and exploratory proof-of-concept evaluations.

Structure Therapeutics reported Phase 2 data for Aleniglipron, showing 16% weight loss at 44 weeks with strong tolerability and no safety signals. Aleniglipron's best-in-class oral efficacy, low discontinuation, and clean safety profile position GPCR as a formidable challenger or acquisition target in obesity therapeutics. Significant risks remain: long, costly Phase 3 trials, uncertain durability of tolerability, and the need for additional capital before commercialization.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Novo Nordisk (NYSE:NVO) has received a broadly neutral assessment from Deutsche Bank and Citi after a series of clinical and commercial updates, with both brokers flagging encouraging but not transformative data from the Danish drugmaker's pipeline. The most substantive clinical update centred on UBT251, Novo's once-weekly experimental injection that works by activating three hormonal pathways, GLP-1, GIP and glucagon, which together regulate blood sugar and appetite.

Global Partners (GLP) possesses solid growth attributes, which could help it handily outperform the market.

The broker retains its hold rating, warning that overall portfolio growth may stall even as the oral weight-loss pill gains traction Jefferies has trimmed its price target on Novo Nordisk (NYSE:NVO), the Danish pharmaceutical giant, to DKK270 from DKK275, maintaining a 'hold' rating ahead of first-quarter results. The change came as the broker flagged mounting uncertainty around GLP-1 pricing, oral Wegovy's launch trajectory and the risk that the new pill cannibalises rather than grows the overall franchise.

“The window to shape the oral GLP-1 market is open now

General Mills (GIS) is rated a soft buy as its valuation appears attractive after a prolonged decline, despite recent underperformance. GLP-1 appetite-suppressing drugs and rising private label popularity pose headwinds to GIS's revenue and brand strength. GIS's fundamentals show a low TTM GAAP PE of 9.21, strong ~12% net income margins, but concerning 6.5% YOY revenue decline and shrinking EPS.

CAH sees GLP-1 drugs boost revenue growth, but margins lag as strong demand lifts volumes without significantly improving profitability.

This gasoline distributor's stock has increased so far in 2026. But how will the current geopolitical tensions threatening oil supply affect its performance?